ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

Six More CCOPS In Funding Range For Recompetition

February 9, 1990

NCI Alternative to Fixed Number Of Grants Not Popular At NIH; AACR Considers New Issues Groups

July 15, 1983

Three CBCCPs Say They’ll Appeal To NC On Termination

March 21, 1980

In Brief: Frederickson Resigns As NIH Director, Says He Wants “One More Career: As Scientist, Physician

June 25, 1981

FDA Plans Safety Reviews Of Newly Approved Drugs; Drug Safety Bills Introduced In Senate.

February 2, 2007

American Cancer Society Publishes CT Screening Guidelines for Lung Cancer

January 11, 2013